Volition Expands Access to Nu.Q® Vet Cancer Test Across America and Asia

Introduction

In a significant boost for canine health diagnostics, VolitionRx Limited, a multinational company renowned for its advancements in epigenetics, has announced the appointment of two new laboratory partners for its Nu.Q® Vet Cancer test. Starting February 2026, this innovative test will be available across all 50 states in the U.S. through the Midwest Veterinary Laboratory, and in Asia via Bioguard's Animal Health Diagnostic Center in Taiwan and China, marking a pivotal expansion in the accessibility of canine cancer detection tools.

New Laboratory Partners

The partnership with the Midwest Veterinary Laboratory, a trusted independent reference lab, will provide pet owners and veterinarians nationwide access to the Nu.Q® Vet Cancer test, allowing for timely identification of cancer in dogs. Meanwhile, Bioguard, recognized for its global contributions to animal health diagnostics, will implement the Nu.Q® testing in its state-of-the-art facility in Asia, the first ISO/IEC 17025 certified animal disease testing laboratory in Taiwan and China. This development is a significant step toward ensuring that cutting-edge diagnostic tools are within reach of a larger pet-owning community.

Importance of Early Cancer Detection

Early detection of canine cancer is crucial for effective treatment. Incorporating the Nu.Q® test into routine veterinary checkups can enable the earlier identification of cancerous conditions, allowing pet owners to make informed decisions about their pets' health care options. As Dr. Tom Butera, CEO of Volition Veterinary Diagnostics Development LLC, stated, "We are delighted to extend the availability of our groundbreaking Nu.Q® technology in both the U.S. and Asia through these well-established reference labs." By facilitating annual checkups or regular wellness exams, veterinarians can detect cancer sooner, improving outcomes for many dogs.

Market Potential

The market for canine cancer screening presents a lucrative opportunity, with estimates putting the Total Addressable Market (TAM) for this sector at approximately $100 million across the U.S., Europe, and Japan. If successful in penetrating the Chinese market as well, this figure could rise to nearly $150 million. The demand for reliable veterinary diagnostic tools is clearer than ever, demonstrating the need for effective solutions like the Nu.Q® test in diagnosing canine cancers.

About Volition

Volition is dedicated to advancing science in the field of epigenetics and offers various diagnostics that can save lives by improving the early detection of diseases across both human and animal populations. Their focus is on providing simple, cost-effective blood tests that can identify and monitor various diseases, including cancers. The company’s innovative approach emphasizes the significance of early detection, which has the potential not only to extend the lives of patients but to enhance their quality of life as well. The company's R&D activities take place in Belgium, with additional offices in the U.S. and London, solidifying its presence in the international healthcare sector.

Conclusion

As VolitionRx Limited extends its testing capabilities through new partnerships, the company continues to demonstrate its commitment to improving animal health outcomes. The Nu.Q® Vet Cancer test holds promise for transforming how veterinarians approach cancer screening in canines, and is set to play a vital role in the ongoing battle against this devastating disease amongst our beloved pets. This progress is not just a win for Volition, but for pet owners everywhere who seek the best for their furry companions.

For more information about Volition and its innovative products, visit their web presence or reach out to their media contact, Louise Batchelor, at +44 (0)7557 774620 for inquiries.